Hypoxia and Rho/Rho-kinase signaling: Lung development versus hypoxic pulmonary hypertension

Advances in Experimental Medicine and Biology

Volumn 543, Issue , 2003, Pages 127-137

  McMurtry, Ivan F ^a   Bauer, Natalie R ^a   Fagan, Karen A ^a   Nagaoka, Tetsutaro ^a   Gebb, Sarah A ^a   Oka, Masahiko ^a  

^a NONE

Author keywords

Fasudil; Lung dysplasia; Pulmonary vasoconstriction; RhoA; Y 27632

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE;

ALTITUDE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; FETUS DEVELOPMENT; GENE EXPRESSION REGULATION; HUMAN; HYPOXIA; LUNG BLOOD FLOW; LUNG DEVELOPMENT; LUNG DYSPLASIA; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0842313242     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-8997-0_9     Document Type: Conference Paper

References (58)

1. Amano M, Fukata Y, and Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 261: 44-51, 2000.
2. Bishop AL, and Hall A. Rho GTPases and their effector proteins. Biochem J 348: 241-255, 2000.
3. Burri PH. Fetal and postnatal development of the lung. Annu Rev Physiol 46: 617-628, 1984.
4. Chen YF, and Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 320: 223-232, 2000.
5. Damron DS, Kanaya N, Homma Y, Kim S-O, and Murray PA. Role of PKC, tyrosine kinases, and Rho kinase in alpha-adrenoreceptor-mediated PASM contraction. Am J Physiol Lung Cell Mol Physiol 283: L1051-1064, 2002.
6. DeVries WC, Seaber AV, and Sealy WC. Unilateral pulmonary emphysema created by ligation of the left pulmonary artery in newborn puppies. Ann Thorac Surg 27: 154-160, 1979.
7. Essler M, Staddon JM, Weber PC, and Aepfelbacher M. Cyclic AMP blocks bacterial lipopolysaccharide-induced myosin light chain phosphorylation in endothelial cells through inhibition of Rho/Rho kinase signaling. J Immunol 164: 6543-6549, 2000.
8. Etienne-Manneville S, and Hall A. Rho GTPases in cell biology. Nature 420: 629-635, 2002.
9. Fagan KA, Oka M, and McMurtry IF. Rho-kinase inhibitor (Y27632) attenuates the development of hypoxia-induced pulmonary hypertension in mice (Abstract). Am J Respir Cell Mol Biol 165: B53, 2002.
10. Fukata Y, Amano M, and Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 22: 32-39, 2001.
11. Gohla A, Schultz G, and Offermanns S. Role for G(12)/G(13) in agonist-induced vascular smooth muscle cell contraction. Circ Res 87: 221-227, 2000.
12. Gong MC, Fujihara H, Somlyo AV, and Somlyo AP. Translocation of rhoA associated with Ca2+ sensitization of smooth muscle. J Biol Chem 272: 10704-10709, 1997.
13. Haworth SG, de Leval M, and Macartney FJ. Hypoperfusion and hyperperfusion in the immature lung. Pulmonary arterial development following ligation of the left pulmonary artery in the newborn pig. J Thorac Cardiovasc Surg 82: 281-292, 1981.
14. Haworth SG, McKenzie SA, and Fitzpatrick ML. Alveolar development after ligation of left pulmonary artery in newborn pig: clinical relevance to unilateral pulmonary artery. Thorax 36: 938-943, 1981.
15. Herget J, Suggett AJ, Leach E, and Barer GR. Resolution of pulmonary hypertension and other features induced by chronic hypoxia in rats during complete and intermittent normoxia. Thorax 33: 468-473, 1978.
16. Hernandez-Perera O, Perez-Sala D, Soria E, and Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 87: 616-622, 2000.
17. Hoeper MM, Galie N, Simonneau G, and Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 1209-1216, 2002.
18. Janssen LJ, Lu-Chao H, and Netherton S. Excitation-contraction coupling in pulmonary vascular smooth muscle involves tyrosine kinase and Rho kinase. Am J Physiol Lung Cell Mol Physiol 280: L666-674, 2001.
19. Jeffery TK, and Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92: 1-20, 2001.
20. Kitazawa T, Eto M, Woodsome TP, and Brautigan DL. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem 275: 9897-9900, 2000.
21. Koyama M, Ito M, Feng J, Seko T, Shiraki K, Takase K, Hartshorne DJ, and Nakano T. Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase. FEBS Lett 475: 197-200, 2000.
22. Le Cras TD, Kim DH, Gebb S, Markham NE, Shannon JM, Tuder RM, and Abman SH. Abnormal lung growth and the development of pulmonary hypertension in the Fawn-Hooded rat. Am J Physiol 277: L709-718, 1999.
23. Le Cras TD, Kim DH, Markham NE, and Abman AS. Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. Am J Physiol Lung Cell Mol Physiol 279: L283-291, 2000.
24. Lee MR, Li L, and Kitazawa T. Cyclic GMP causes Ca2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. J Biol Chem 272: 5063-5068, 1997.
25. Lu J, Landerholm TE, Wei JS, Dong X-R, Wu S-P, Liu X, Nagata K-i, Inagaki M, and Majesky MW. Coronary Smooth Muscle Differentiation from Proepicardial Cells Requires RhoA-Mediated Actin Reorganization and p160 Rho-Kinase Activity. Developmental Biology 240: 404-418, 2001.
26. Massaro GD, Olivier J, Dzikowski C, and Massaro D. Postnatal development of lung alveoli: suppression by 13% O2 and a critical period. Am J Physiol Lung Cell Mol Physiol 258: L321-327, 1990.
27. Massaro GD, and Massaro D. Formation of Pulmonary Alveoli and Gas-Exchange Surface Area: Quantitation and Regulation. Annu Rev Physiol 58: 73-92, 1996.
28. Meyrick B, and Reid L. Pulmonary arterial and alveolar development in normal postnatal rat lung. Am Rev Respir Dis 125: 468-473, 1982.
29. Moon SY, and Zheng Y. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol 13: 13-22, 2003.
30. Moore KA, Huang S, Kong Y, Sunday ME, and Ingber DE. Control of Embryonic Lung Branching Morphogenesis by the Rho Activator, Cytotoxic Necrotizing Factor 1. Journal of Surgical Research 104: 95-100, 2002.
31. Morio Y, Muramatsu M, Takahashi K, Teramoto S, Oka T, and Fukuchi Y. Distal airspace enlargement in the fawn-hooded rat: influences of aging and alveolar wall destruction. Respiration 68: 78-86, 2001.
32. Morio Y, and McMurtry IF. Ca(2+) release from ryanodine-sensitive store contributes to mechanism of hypoxic vasoconstriction in rat lungs. J Appl Physiol 92: 527-534, 2002.
33. Morio Y, Oka M, and McMurtry IF. A selective Rho-kinase inhibitor, Y-27632, is an effective vasodilator of chronically hypoxic hypertensive rat lungs (Abstract). Faseb J 16: A74, 2002.
34. Nagaoka T, Muramatsu M, Sato K, McMurtry I, Oka M, and Fukuchi Y. Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats. Respir Physiol 127: 53-60, 2001.
35. Niiro N, Koga Y, and Ikebe M. Agonist-induced changes in the phosphorylation of the myosin-binding subunit of myosin light chain phosphatase and CPI17, two regulatory factors of myosin light chain phosphatase, in smooth muscle. Biochem J 369: 117-128, 2003.
36. Oka M, Morris KG, and McMurtry IF. NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension. J Appl Physiol 75: 1075-1080, 1993.
37. Oka M, Morio Y, Morris KG, and McMurtry I. Acute hemodynamic effects of Y27632, a selective Rho-kinase inhibitor, in chronically hypoxic pulmonary hypertensive rats (Abstract). Faseb J 16: A74, 2002.
38. Pfitzer G. Invited review: regulation of myosin phosphorylation in smooth muscle. J Appl Physiol 91: 497-503, 2001.
39. Resta TC, Chicoine LG, Omdahl JL, and Walker BR. Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. Am J Physiol 276: H699-708, 1999.
40. Robertson TP, Dipp M, Ward JP, Aaronson PI, and Evans AM. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br J Pharmacol 131: 5-9, 2000.
41. Sakurada S, Okamoto H, Takuwa N, Sugimoto N, and Takuwa Y. Rho activation in excitatory agonist-stimulated vascular smooth muscle. Am J Physiol Cell Physiol 281: C571-578, 2001.
42. Sasaki Y, Suzuki M, and Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacology & Therapeutics 93: 225-232, 2002.
43. Sato K, Webb S, Tucker A, Rabinovitch M, O'Brien RF, McMurtry IF, and Stelzner TJ. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 145: 793-797, 1992.
44. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, and Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 275: 21722-21729, 2000.
45. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, and Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res 89: 488-495, 2001.
46. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39: 319-327, 2002.
47. Somlyo AP, and Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 522: 177-185, 2000.
48. Stelzner TJ, O'Brien RF, Yanagisawa M, Sakurai T, Sato K, Webb S, Zamora M, McMurtry IF, and Fisher JH. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 262: L614-620, 1992.
49. Takemoto M, Sun J, Hiroki J, Shimokawa H, and Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106: 57-62, 2002.
50. Tyler RC, Muramatsu M, Abman SH, Stelzner TJ, Rodman DM, Bloch KD, and McMurtry IF. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 276: L297-303, 1999.
51. van Nieuw Amerongen GP, and van Hinsbergh VW. Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 21: 300-311, 2001.
52. Vicencio AG, Eickelberg O, Stankewich MC, Kashgarian M, and Haddad GG. Regulation of TGF-beta ligand and receptor expression in neonatal rat lungs exposed to chronic hypoxia. J Appl Physiol 93: 1123-1130, 2002.
53. Wang Z, Jin N, Ganguli S, Swartz DR, Li L, and Rhoades RA. Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am J Respir Cell Mol Biol 25: 628-635, 2001.
54. Wei L, Imanaka-Yoshida K, Wang L, Zhan S, Schneider MD, DeMayo FJ, and Schwartz RJ. Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor disrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation. Development 129: 1705-1714, 2002.
55. Wettschureck N, and Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 80: 629-638, 2002.
56. Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, and Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 35: 313-318, 2000.
57. Yuan JX-J, and Rubin LJ. Pathophysiology of Pulmonary Hypertension. In: Respiratory-Circulatory Interactions in Health and Disease, edited by Scharf SM and Magder S. New York: Marcel Dekker, Inc, 2001, p. 447-490.
58. Zhao Z, and Rivkees SA. Rho-associated kinases play an essential role in cardiac morphogenesis and cardiomyocyte proliferation. Dev Dyn 226: 24-32, 2003.